Corrigendum to "In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys" [Biochem. Pharmacol. 138 (2017) 107-118].
 
				Authors: Chourey S,  Ye Q,  Reddy CN,  Cossette C,  Gravel S,  Zeller M,  Slobodchikova I,  Vuckovic D,  Rokach J,  Powell WS
 
				
				
				
				Affiliations
				
					1 Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA. 
 
 
 
 
 2 Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada. 
 
 
 
 
 3 Department of Chemistry, Purdue University, West Lafayette, IN 47906, USA. 
 
 
 
 
 4 Department of Chemistry and Biochemistry and PERFORM Centre, Concordia University, 7141 Sherbrooke St. W., Montréal, QC H4B 1R6, Canada. 
 
 
 
 
 5 Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada. Electronic address: william.powell@mcgill.ca. 
				
				
				
				Description
					
					Corrigendum to "In vivo a-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys" [Biochem. Pharmacol. 138 (2017) 107-118].
          Biochem Pharmacol. 2018 08;154:174
     Authors: Chourey S, Ye Q, Reddy CN, Cossette C, Gravel S, Zeller M, Slobodchikova I, Vuckovic D, Rokach J, Powell WS
     PMID: 29754018 [PubMed]
				  
				
				
				
				Links
				PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29754018?dopt=Abstract
 
				
					DOI: 10.1016/j.bcp.2018.04.025